Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.

Impact · against what's priced in

The news is largely neutral as the market already prices in CRISPR's cash runway, revenue sharing with Vertex, and the pediatric label expansion. Cathie Wood's modest accumulation represents a minor institutional signal but does not fundamentally shift the valuation hurdles regarding pipeline success.

CRSP+0.00: Already priced in
The price assumes: The $2.56 billion pro forma cash position

Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.

What matters in this story

Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.

Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.

What matters in this story

Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.

How each ticker is affected

Connected tickers

Track these names every morning.

ARDX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Ardelyx (ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026

Oruka Therapeutics: The Psoriasis Market Is Becoming A Barbell, And ORKA-001 Owns The Far End

UNCY SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share

Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.

What matters in this story

Next reads from the same story arc

Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.

Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.

What matters in this story

Next reads from the same story arc

Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.

How each ticker is affected

Connected tickers

Track these names every morning.

ARDX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Ardelyx (ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026

Oruka Therapeutics: The Psoriasis Market Is Becoming A Barbell, And ORKA-001 Owns The Far End

UNCY SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share